Clinical Trial Results TV
April 4, 2011: Dr. A Michael Lincoff and Dr. C. Michael Gibson discuss: Selective Inhibition of Delta Protein Kinase C to Reduce Infar
Dr. A Michael Lincoff and Dr. C. Michael Gibson discuss: Selective Inhibition of Delta
Protein Kinase C to Reduce Infarct Size after Primary Percutaneous Intervention for Acute
Myocardial Infarction: The PROTECTION-AMI Phase IIb Clinical Trial at ACC 2011.

C5Research: Anthera, AstraZeneca, Atherosys, Bristol-Myers Squibb (BMS), Centocor, Cordis,
Guidant, Heartscape, J&K, KAI Pharma, Lilly, Mannkind, Medicines Company, Medtronic,
Novartis, Novo Nordisk, Pfizer, Resverlogix, Roche/Genentech, Sankyo, Sanofi-Aventis,
Schering-Plough, Scios, Takeda, VasoGenix. Consultant: Schering-Plough, Bioline, BMS,
Merck, Baxter, Aztra Zeneca, Roche.

[ Download video ]


Video Statistics
0 out of 5

1 Star 2 Star 3 Star 4 Star 5 Star

click a star to vote
This submission has received 0 total votes.

These statistics are updated nightly. The last update ran on
11-22-2017 EST at 1 am.

Additional Files
Filename File Description Action
No additional files available

Comments [ login to comment ]
No comments have been submitted